Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4533) 4533
Publication (320) 320
Book Review (108) 108
Book Chapter (18) 18
Conference Proceeding (16) 16
Magazine Article (13) 13
Book / eBook (6) 6
Dissertation (2) 2
Web Resource (2) 2
Paper (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3095) 3095
muscarinic antagonists - therapeutic use (2169) 2169
male (2028) 2028
index medicus (1925) 1925
animals (1544) 1544
female (1543) 1543
pharmacology & pharmacy (1139) 1139
middle aged (960) 960
aged (858) 858
adult (747) 747
treatment outcome (743) 743
rats (678) 678
urinary bladder, overactive - drug therapy (614) 614
muscarinic antagonists - pharmacology (593) 593
muscarinic antagonists - administration & dosage (554) 554
muscarinic antagonists - adverse effects (542) 542
overactive bladder (538) 538
urology & nephrology (533) 533
pulmonary disease, chronic obstructive - drug therapy (459) 459
neurosciences (428) 428
dose-response relationship, drug (423) 423
urinary incontinence (422) 422
efficacy (397) 397
muscarinic receptors (367) 367
drug therapy (366) 366
benzhydryl compounds - therapeutic use (353) 353
double-blind (353) 353
care and treatment (350) 350
drug therapy, combination (349) 349
receptors, muscarinic - drug effects (348) 348
mice (346) 346
acetylcholine (345) 345
quality of life (335) 335
double-blind method (332) 332
respiratory system (329) 329
tolterodine tartrate (322) 322
aged, 80 and over (304) 304
time factors (301) 301
research (300) 300
receptors, muscarinic - metabolism (299) 299
cresols - therapeutic use (298) 298
administration, inhalation (288) 288
bronchodilator agents - therapeutic use (280) 280
tolterodine (279) 279
acetylcholine receptors (277) 277
analysis (276) 276
urinary incontinence - drug therapy (275) 275
muscarinic antagonists (261) 261
copd (257) 257
psychiatry (256) 256
in vitro techniques (249) 249
receptors (249) 249
obstructive pulmonary-disease (248) 248
chronic obstructive pulmonary disease (243) 243
safety (235) 235
rats, sprague-dawley (234) 234
adolescent (232) 232
tiotropium (232) 232
medicine, general & internal (231) 231
mandelic acids - therapeutic use (227) 227
lung diseases, obstructive (224) 224
quality-of-life (223) 223
pharmacology (222) 222
phenylpropanolamine - therapeutic use (222) 222
disease models, animal (221) 221
oxybutynin (221) 221
atropine - therapeutic use (217) 217
medicine & public health (211) 211
severity of illness index (207) 207
pulmonary disease, chronic obstructive - physiopathology (201) 201
guinea pigs (196) 196
asthma (195) 195
health aspects (195) 195
quinuclidines - therapeutic use (193) 193
atropine - pharmacology (190) 190
urology (189) 189
rats, wistar (188) 188
management (186) 186
rodents (186) 186
scopolamine (185) 185
bronchodilator agents - administration & dosage (184) 184
muscarinic agonists - pharmacology (184) 184
drugs (182) 182
cholinergic antagonists - therapeutic use (179) 179
child (176) 176
dosage and administration (176) 176
medicine (175) 175
bladder (174) 174
atropine (168) 168
alzheimers-disease (165) 165
solifenacin succinate (165) 165
prospective studies (164) 164
symptoms (162) 162
article (159) 159
incontinence (159) 159
studies (159) 159
urinary bladder, overactive - physiopathology (159) 159
toxicology (158) 158
young adult (158) 158
adrenergic beta-2 receptor agonists - therapeutic use (157) 157
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4311) 4311
German (73) 73
Russian (41) 41
French (38) 38
Spanish (29) 29
Japanese (22) 22
Chinese (15) 15
Danish (6) 6
Italian (6) 6
Polish (6) 6
Dutch (5) 5
Portuguese (3) 3
Bulgarian (2) 2
Czech (2) 2
Finnish (2) 2
Swedish (2) 2
Hebrew (1) 1
Hungarian (1) 1
Norwegian (1) 1
Romanian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Pharmacology and therapeutics of bronchodilators
by Cazzola, Mario and Page, Clive P and Calzetta, Luigino and Matera, M. Gabriella
Pharmacological Reviews, ISSN 0031-6997, 2012, Volume 64, Issue 3, pp. 450 - 504
Bronchodilators are central in the treatment of of airways disorders. They are the mainstay of the current management of chronic obstructive pulmonary disease... 
BETA-ADRENOCEPTOR AGONISTS | RANDOMIZED CONTROLLED-TRIALS | OBSTRUCTIVE PULMONARY-DISEASE | METHACHOLINE-INDUCED BRONCHOCONSTRICTION | LONG-ACTING BETA-AGONISTS | ATRIAL-NATRIURETIC-PEPTIDE | INHALED BETA-ADRENOCEPTOR AGONIST | EXERCISE-INDUCED BRONCHOCONSTRICTION | PHARMACOLOGY & PHARMACY | AIRWAY SMOOTH-MUSCLE | GUINEA-PIG TRACHEA | Bronchodilator Agents - therapeutic use | Asthma - metabolism | Xanthines - adverse effects | Humans | Muscarinic Antagonists - adverse effects | Adrenergic beta-Agonists - pharmacology | Bronchodilator Agents - pharmacology | Muscarinic Antagonists - therapeutic use | Xanthines - therapeutic use | Xanthines - pharmacology | Asthma - drug therapy | Drug Discovery | Asthma - genetics | Animals | Muscarinic Antagonists - pharmacology | Adrenergic beta-Agonists - therapeutic use | Pulmonary Disease, Chronic Obstructive - metabolism | Bronchodilator Agents - adverse effects | Adrenergic beta-Agonists - adverse effects | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Pulmonary Disease, Chronic Obstructive - genetics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction
by Oelke, Matthias and Bachmann, Alexander and Descazeaud, Aurélien and Emberton, Mark and Gravas, Stavros and Michel, Martin C and N'Dow, James and Nordling, Jørgen and de la Rosette, Jean J and European Association of Urology
European Urology, ISSN 0302-2838, 2013, Volume 64, Issue 1, pp. 118 - 140
Abstract Objective To present a summary of the 2013 version of the European Association of Urology guidelines on the treatment and follow-up of male lower... 
Urology | α-Adrenoreceptor antagonist | Desmopressin | Botulinum toxin injections | Transurethral resection of the prostate | Ethanol injections | 5α-Reductase inhibitor | Transurethral needle ablation | Prostate stent | Transurethral incision of the prostate | Muscarinic receptor antagonist | Open prostatectomy | Laser prostatectomy | Benign prostatic hyperplasia | Transurethral microwave therapy | Bipolar transurethral resection of the prostate | Lower urinary tract symptoms | Phosphodiesterase inhibitors | RANDOMIZED CONTROLLED-TRIAL | alpha-Adrenoreceptor antagonist | DIODE-LASER | HOLMIUM LASER ENUCLEATION | PHOTOSELECTIVE VAPORIZATION | 5 alpha-Reductase inhibitor | ALUMINUM-GARNET VAPOENUCLEATION | TOLTERODINE EXTENDED-RELEASE | OVERACTIVE BLADDER SYMPTOMS | TITANYL-PHOSPHATE LASER | MONOPOLAR TRANSURETHRAL RESECTION | DOUBLE-BLIND | UROLOGY & NEPHROLOGY | Severity of Illness Index | Phosphodiesterase Inhibitors - therapeutic use | Risk Reduction Behavior | Humans | Prostatic Hyperplasia - therapy | Lower Urinary Tract Symptoms - physiopathology | Male | Transurethral Resection of Prostate - adverse effects | Treatment Outcome | 5-alpha Reductase Inhibitors - therapeutic use | Muscarinic Antagonists - therapeutic use | Lower Urinary Tract Symptoms - therapy | Transurethral Resection of Prostate - standards | Urology - standards | Urological Agents - adverse effects | Prostatic Hyperplasia - diagnosis | Adrenergic alpha-1 Receptor Antagonists - therapeutic use | Urinary Catheterization - standards | Lower Urinary Tract Symptoms - diagnosis | Prostatic Hyperplasia - physiopathology | Stents - standards | Watchful Waiting - standards | Urological Agents - therapeutic use | Practice guidelines (Medicine) | Medical colleges | Bipolar disorder | Desmopressin acetate | Ablation (Surgery)
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD
by Wedzicha, Jadwiga A and Banerji, Donald and Chapman, Kenneth R and Vestbo, Jørgen and Roche, Nicolas and Ayers, R. Timothy and Thach, Chau and Fogel, Robert and Patalano, Francesco and Vogelmeier, Claus F and FLAME Investigators
The New England Journal of Medicine, ISSN 0028-4793, 06/2016, Volume 374, Issue 23, pp. 2222 - 2234
This randomized trial compared a long-acting beta-agonist (LABA) plus a glucocorticoid with a LABA plus a long-acting muscarinic antagonist for preventing... 
MEDICINE, GENERAL & INTERNAL | OBSTRUCTIVE PULMONARY-DISEASE | EFFICACY | TO-SEVERE COPD | BLOOD EOSINOPHILS | SAFETY | PARALLEL-GROUP | INHALED CORTICOSTEROIDS | LUNG-FUNCTION | DOUBLE-BLIND | EXACERBATIONS | Glycopyrrolate - adverse effects | Indans - adverse effects | Pulmonary Disease, Chronic Obstructive - mortality | Glucocorticoids - therapeutic use | Double-Blind Method | Glycopyrrolate - therapeutic use | Humans | Middle Aged | Administration, Inhalation | Male | Fluticasone-Salmeterol Drug Combination - therapeutic use | Muscarinic Antagonists - therapeutic use | Indans - therapeutic use | Fluticasone-Salmeterol Drug Combination - adverse effects | Quinolones - adverse effects | Quinolones - therapeutic use | Adrenergic beta-2 Receptor Agonists - therapeutic use | Female | Aged | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Care and treatment | Indacaterol | Dosage and administration | Salmeterol | Respiratory therapy | Acetylcholine receptors (muscarinic) | Glucocorticoids | Lung diseases | Fluticasone | Preventive medicine | Patients | Inhalation | Obstructive lung disease | Comparative studies | Chronic obstructive pulmonary disease | Pharmaceuticals | Life Sciences | Human health and pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Efficacy and Tolerability of Mirabegron, a beta(3)-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European-Australian Phase 3 Trial
by Khullar, V and Amarenco, G and Angulo, JC and Cambronero, J and Hoye, K and Milsom, I and Radziszewski, P and Rechberger, T and Boerrigter, P and Drogendijk, T and Wooning, M and Chapple, C and Sahlgrenska akademin and Göteborgs universitet and Gothenburg University and Institute of Clinical Sciences, Section for the Health of Women and Children, Department of Obstetrics and Gynecology and Sahlgrenska Academy and Institutionen för kliniska vetenskaper, sektionen för kvinnors och barns hälsa, Avdelningen för obstetrik och gynekologi
EUROPEAN UROLOGY, ISSN 0302-2838, 02/2013, Volume 63, Issue 2, pp. 283 - 295
Background: Mirabegron, a beta(3)-adrenoceptor agonist, has been developed for the treatment of overactive bladder (OAB). Objective: To assess the efficacy and... 
METAANALYSIS | URINARY-TRACT SYMPTOMS | Overactive bladder (OAB) | beta-Adrenoceptor agonist | DOUBLE-BLIND | UROLOGY & NEPHROLOGY | HEART-RATE | Mirabegron | Single-Blind Method | Cresols - therapeutic use | Humans | Middle Aged | Male | Muscarinic Antagonists - therapeutic use | Thiazoles - therapeutic use | Phenylpropanolamine - therapeutic use | Urinary Bladder, Overactive - drug therapy | Tolterodine Tartrate | Urination - drug effects | Acetanilides - therapeutic use | Female | Surveys and Questionnaires | Urinary Incontinence, Urge - drug therapy | Benzhydryl Compounds - therapeutic use | Urinary Bladder, Overactive - complications | Double-Blind Method | Europe | Treatment Outcome | Adrenergic beta-3 Receptor Agonists - therapeutic use | Delayed-Action Preparations - therapeutic use | Quality of Life | Aged | Urinary Incontinence, Urge - etiology | Australia | Clinical Medicine | Urologi och njurmedicin | Klinisk medicin | Urology and Nephrology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: The GLOW2 study
by Kerwin, Edward and Hébert, Jacques and Gallagher, Nicola and Martin, Carmen and Overend, Tim and Alagappan, Vijay K.T and Lu, Yimeng and Banerji, Donald
European Respiratory Journal, ISSN 0903-1936, 11/2012, Volume 40, Issue 5, pp. 1106 - 1114
NVA237 (glycopyrronium bromide) is a once-daily long-acting muscarinic antagonist (LAMA) in development for chronic obstructive pulmonary disease (COPD). The... 
Tiotropium | NVA237 | Chronic obstructive pulmonary disease | Long-acting muscarinic antagonist | Bronchodilator | Glycopyrronium bromide | LUNG-FUNCTION | glycopyrronium bromide | tiotropium | SALMETEROL | DECLINE | TRIAL | OBSTRUCTIVE PULMONARY-DISEASE | IMPACT | RESPIRATORY SYSTEM | EXACERBATIONS | long-acting muscarinic antagonist | chronic obstructive pulmonary disease | HEALTH-STATUS | Bronchodilator Agents - therapeutic use | Glycopyrrolate - adverse effects | Double-Blind Method | Glycopyrrolate - therapeutic use | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Male | Muscarinic Antagonists - therapeutic use | Female | Bronchodilator Agents - adverse effects | Scopolamine Derivatives - therapeutic use | Scopolamine Derivatives - adverse effects | Pulmonary Disease, Chronic Obstructive - drug therapy | Tiotropium Bromide | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Antidepressant Effects of the Muscarinic Cholinergic Receptor Antagonist Scopolamine: A Review
by Drevets, Wayne C and Zarate, Carlos A and Furey, Maura L
Biological Psychiatry, ISSN 0006-3223, 2013, Volume 73, Issue 12, pp. 1156 - 1163
The muscarinic cholinergic receptor system has been implicated in the pathophysiology of depression, with physiological evidence indicating this system is... 
Psychiatry | Antidepressant | muscarinic | bipolar | unipolar | scopolamine | cholinergic | BEHAVIORAL DESPAIR TEST | PSYCHIATRY | AFFECTIVE-DISORDERS | SLEEP-DEPRIVATION | MAJOR DEPRESSION | ANTI-DEPRESSANTS | NEUROSCIENCES | LOW-DOSE PHYSOSTIGMINE | REM INDUCTION TEST | BASAL FOREBRAIN | GENDER-DIFFERENCES | MATCHED CONTROLS | Antidepressive Agents - therapeutic use | Young Adult | Depression - drug therapy | Scopolamine Hydrobromide - therapeutic use | Humans | Middle Aged | Adolescent | Adult | Female | Male | Muscarinic Antagonists - therapeutic use | Randomized Controlled Trials as Topic | Scopolamine | Antidepressants | Analysis | Depression, Mental | Physiological aspects | Bipolar disorder | Gene expression | Health aspects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony)
by Abrams, Paul and Kelleher, Con and Staskin, David and Rechberger, Tomasz and Kay, Richard and Martina, Reynaldo and Newgreen, Donald and Paireddy, Asha and van Maanen, Rob and Ridder, Arwin
European Urology, ISSN 0302-2838, 2014, Volume 67, Issue 3, pp. 577 - 588
Abstract Background Combining the β3-adrenoceptor agonist mirabegron and the antimuscarinic (AM) agent solifenacin may improve efficacy in the treatment of... 
Urology | Overactive bladder | Solifenacin | Combination therapy | Mirabegron | OUTLET OBSTRUCTION | TRIAL | THERAPY | URINARY-TRACT SYMPTOMS | MEN | UROLOGY & NEPHROLOGY | TAMSULOSIN | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Urodynamics - drug effects | Male | Muscarinic Antagonists - therapeutic use | Thiazoles - therapeutic use | Adrenergic beta-3 Receptor Agonists - adverse effects | Thiazoles - adverse effects | Urinary Bladder, Overactive - drug therapy | Urological Agents - adverse effects | Time Factors | Urinary Bladder, Overactive - physiopathology | Urination - drug effects | Acetanilides - therapeutic use | Adult | Female | Acetanilides - adverse effects | Urological Agents - therapeutic use | Urinary Bladder, Overactive - diagnosis | Double-Blind Method | Europe | Treatment Outcome | Solifenacin Succinate - therapeutic use | Adrenergic beta-3 Receptor Agonists - therapeutic use | Solifenacin Succinate - adverse effects | Urinary Bladder - physiopathology | Urinary Bladder - drug effects | Aged | Drug Combinations
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights